Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Peloton Therapeutics Inc. A Fully Owned Subsidiary Of Merck Sharp & Dohme LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by a distinct examiner, DAHLIN, HEATHER RAQUEL, in a distinct art unit. This action represents the current pending status for the subsidiary. The focus on this pending matter indicates a very specific prosecution effort in the biotechnology sector. The Biotechnology & Pharmaceuticals technology area often involves complex biological data and rigorous examination standards.
DAHLIN, HEATHER RAQUEL is the busiest examiner with 1 pending action. This figure is the same as the total number of pending office actions. The distinct art unit involved indicates a highly specific technical focus for this pending matter. With the distinct examiner and the distinct art unit, the prosecution is entirely centralized. Practitioners should tailor their strategy to the specific requirements of the examiner managing this Biotechnology & Pharmaceuticals case, as there are no other active matters to consider in this portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLIN, HEATHER RAQUEL | 1 | 41.1% | +47.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19304725 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | DAHLIN, HEATHER RAQUEL | 81d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19304725 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | DAHLIN, HEATHER RAQUEL | 1629 | §103 | Final Rejection | 81d overdue | Pending | Aug 20, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial